Genenta Science (GNTA) Competitors $3.74 -0.26 (-6.60%) As of 01/31/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GNTA vs. ENGN, SOPH, ATYR, DSGN, IMMP, ELDN, CTNM, YMAB, HRTX, and ITOSShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include enGene (ENGN), SOPHiA GENETICS (SOPH), Atyr PHARMA (ATYR), Design Therapeutics (DSGN), Immutep (IMMP), Eledon Pharmaceuticals (ELDN), Contineum Therapeutics (CTNM), Y-mAbs Therapeutics (YMAB), Heron Therapeutics (HRTX), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. enGene SOPHiA GENETICS Atyr PHARMA Design Therapeutics Immutep Eledon Pharmaceuticals Contineum Therapeutics Y-mAbs Therapeutics Heron Therapeutics iTeos Therapeutics enGene (NASDAQ:ENGN) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Is ENGN or GNTA more profitable? Genenta Science's return on equity of 0.00% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -16.69% -14.27% Genenta Science N/A N/A N/A Does the MarketBeat Community believe in ENGN or GNTA? enGene received 9 more outperform votes than Genenta Science when rated by MarketBeat users. Likewise, 100.00% of users gave enGene an outperform vote while only 87.50% of users gave Genenta Science an outperform vote. CompanyUnderperformOutperformenGeneOutperform Votes16100.00% Underperform VotesNo VotesGenenta ScienceOutperform Votes787.50% Underperform Votes112.50% Which has more risk and volatility, ENGN or GNTA? enGene has a beta of -0.65, indicating that its stock price is 165% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Do insiders & institutionals have more ownership in ENGN or GNTA? 64.2% of enGene shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 13.7% of enGene shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate ENGN or GNTA? enGene presently has a consensus target price of $29.78, suggesting a potential upside of 344.44%. Genenta Science has a consensus target price of $25.00, suggesting a potential upside of 610.23%. Given Genenta Science's higher possible upside, analysts plainly believe Genenta Science is more favorable than enGene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, ENGN or GNTA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$55.14M-$0.58-11.55Genenta ScienceN/AN/A-$12.60MN/AN/A Does the media favor ENGN or GNTA? In the previous week, enGene had 3 more articles in the media than Genenta Science. MarketBeat recorded 6 mentions for enGene and 3 mentions for Genenta Science. enGene's average media sentiment score of 0.66 beat Genenta Science's score of 0.29 indicating that enGene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryenGene beats Genenta Science on 8 of the 14 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.38M$3.05B$5.58B$9.12BDividend YieldN/A1.84%5.31%3.99%P/E RatioN/A36.8280.0317.24Price / SalesN/A319.021,259.7283.26Price / CashN/A190.0245.9637.70Price / Book2.914.125.124.70Net Income-$12.60M-$40.99M$111.40M$224.47M7 Day Performance-17.56%-0.43%2.30%-0.19%1 Month Performance-19.08%0.94%3.13%0.57%1 Year Performance-11.11%-1.69%24.60%20.35% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science2.2699 of 5 stars$3.52-12.0%$25.00+610.2%-12.7%$64.38MN/A0.007Short Interest ↑Gap UpENGNenGene3.052 of 5 stars$6.77-5.4%$29.78+339.8%-14.5%$299.37MN/A-11.6731Short Interest ↓News CoverageHigh Trading VolumeSOPHSOPHiA GENETICS2.8195 of 5 stars$4.48+6.7%$7.40+65.2%-23.7%$292.88M$64.49M-4.11520Short Interest ↓Gap DownHigh Trading VolumeATYRAtyr PHARMA2.4713 of 5 stars$3.46-3.6%$19.25+456.4%N/A$290.43M$350,000.00-3.6853Short Interest ↑News CoveragePositive NewsDSGNDesign Therapeutics2.1546 of 5 stars$5.06+1.8%$7.00+38.3%+104.6%$286.50MN/A-5.9540Short Interest ↑News CoverageGap DownIMMPImmutep1.8904 of 5 stars$1.94-1.3%$8.50+338.1%-3.7%$282.39M$5.14M0.002,021News CoverageELDNEledon Pharmaceuticals3.094 of 5 stars$4.66+5.2%$16.00+243.3%+153.9%$278.39MN/A-2.3210Analyst ForecastShort Interest ↓CTNMContineum Therapeutics3.2561 of 5 stars$10.78-3.6%$29.25+171.3%N/A$277.91M$50M0.0031Upcoming EarningsYMABY-mAbs Therapeutics2.1259 of 5 stars$6.15-1.6%$20.89+239.7%-53.3%$275.46M$84.82M-11.39150HRTXHeron Therapeutics3.7599 of 5 stars$1.81-1.1%$5.67+213.1%-29.5%$275.30M$127.04M-10.05300Analyst DowngradeNews CoverageITOSiTeos Therapeutics4.117 of 5 stars$7.53-1.4%$22.25+195.5%-24.2%$275.07M$12.60M-2.3990Short Interest ↓Positive News Related Companies and Tools Related Companies enGene Competitors SOPHiA GENETICS Competitors Atyr PHARMA Competitors Design Therapeutics Competitors Immutep Competitors Eledon Pharmaceuticals Competitors Contineum Therapeutics Competitors Y-mAbs Therapeutics Competitors Heron Therapeutics Competitors iTeos Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNTA) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
